BIOMAT Database Logo BIOMAT Database Logo

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. 2005

T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Rue Héger-Bordet 1, 1000 Bruxelles, Belgium. thierry.berghmans@bordet.be

Few chemotherapeutic agents have demonstrated their efficacy in malignant mesothelioma. The cisplatin plus doxorubicin combination has one of the highest response rates. Epirubicin is an anthracyclin, analogous to doxorubicin, with a different toxicologic pattern. As there are no data on the activity of the combination cisplatin plus epirubicin in malignant mesothelioma, the European Lung Cancer Working Party (ELCWP) designed a phase II study with response rate as primary objective. Sixty-nine eligible patients with malignant pleural mesothelioma were centrally registered. The majority of the patients were male (n=59), had a Karnofsky performance status of 80 or more (n=62) and presented with an epithelial histologic subtype (n=43). Median age was 62 years. In nine patients, metastases were documented at the initial work-up, mainly in bone, lung and skin. Three hundred and twenty-four cycles of chemotherapy were administered. The main toxicities were nausea and vomiting, neutropenia and alopecia. Among 63 assessable patients, response rate was 19.0% (95% confidence interval [CI] 9-29%). Median survival was 13.3 months. In multivariate analysis, poor prognostic factors for survival were neutrophil count and CALGB groups 4-6. In conclusion, cisplatin plus epirubicin appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008654 Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) Mesotheliomas
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010997 Pleural Neoplasms Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms. Neoplasms, Pleural,Neoplasm, Pleural,Pleural Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
June 2005, American journal of clinical oncology,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
September 2018, Clinical lung cancer,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
October 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
October 2021, Journal for immunotherapy of cancer,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
July 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.
April 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
August 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
May 2008, Japanese journal of clinical oncology,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
February 2002, British journal of cancer,
T Berghmans, and J J Lafitte, and M Paesmans, and B Stach, and M C Berchier, and P Wackenier, and J Lecomte, and T Collon, and P Mommen, and J P Sculier, and
[Vinorelbine in patients with malignant pleural mesothelioma--a phase II study].
August 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Copied contents to your clipboard!